BSECompany Update22 Oct 2026 · 22 Oct 2026, 01:25 pm

Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the "Company")

Natco Pharma Ltd · 524816

✦ AI SummaryFundraise

Natco Pharma Ltd has announced the closure of its Rights Issue, which opened on October 12, 2026, and will close on October 22, 2026. The issue aims to raise up to Rs.12,794 million through the issuance of equity shares at Rs.750 each.

Analysis Scores

Earnings Impact2/10
Growth Catalyst3/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk2/10
Liquidity Impact8/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Natco Pharma Ltd - 524816 - Intimation Of Closure Of The Issue Period Of The Rights Issue Of NATCO Pharma Limited (The 'Company')

Attachments (1)

📄

0b5f6727-b55a-490a-9f54-05ab01074a00.pdf

pdf

Download →
View document text
22nd October 2026 Manager – Listing Department Manager – Listing BSE Ltd. National Stock Exchange of India Ltd Mumbai 400 001 Mumbai 400 051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir/Madam, Sub: Intimation of closure of the Issue period of the Rights Issue of NATCO Pharma Limited (the “Company”) This is to inform you that the meeting of the Board of Directors of the Company held on 25th September, 2026 approved the terms of the issuance of equity shares of the Company of face value of Rs.2/- each for cash at a price of Rs.750/- each by way of Rights Issue for an amount aggregating up to Rs.12,794 millions ("Issue"), in accordance with the Companies Act, 2013 and the rules made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, and other applicable laws. In view thereof, please note that the Issue opened on Monday, October 12, 2026 and will close today i.e. Thursday, October, 22, 2026. We request you to kindly take the above information on record. Thanking you Yours faithfully For NATCO Pharma Limited Ch. Venkat Ramesh Company Secretary & Compliance Officer